Literature DB >> 26182825

Strategies for the safe use of colistin.

Jessica K Ortwine1,2, Jesse D Sutton3,4, Keith S Kaye5,6, Jason M Pogue6,7.   

Abstract

Colistin has re-emerged as an essential antibiotic for the treatment of carbapenem-resistant Gram-negative infections. Unfortunately, its utility is limited by high rates of nephrotoxicity, even at potentially therapeutic concentrations, and an overall lack of understanding on how to optimally administer the agent. In this review, recent advancements in the understanding of the safety and efficacy of colistin are discussed and strategies and suggestions on how to balance the two are described.

Entities:  

Keywords:  carbapenem-resistance; colistimethate; colistin; nephrotoxicity; pharmacokinetics; polymyxin

Mesh：

Substances：

Year:  2015        PMID： 26182825     DOI： 10.1586/14787210.2015.1070097

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  7 in total

1.  Colistin induced acute kidney injury in critically ill children: a prospective study utilizing RIFLE criteria.

Authors:  Sharifzadeh Meysam; Zahra Khosravi; Roshanak Rashti; Mostafa Qorbani; Farahnak Assadi; Alireza Hayatshahi; Tanzifi Parin; Toktam Faghihi
Journal:  Daru       Date:  2021-11-22       Impact factor: 4.088

2.  Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.

Authors:  Alan Forrest; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; David L Paterson; Jian Li; Fernanda P Silveira; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections.

Authors:  Heather Henderson; Courtney L Luterbach; Eric Cober; Sandra S Richter; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Anthony Harris; Sonia Napravnik; David Van Duin
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

4.  Inhibition of New Delhi Metallo-β-Lactamase 1 (NDM-1) Producing Escherichia coli IR-6 by Selected Plant Extracts and Their Synergistic Actions with Antibiotics.

Authors:  Brinda Chandar; Sundar Poovitha; Kaliappan Ilango; Ramasamy MohanKumar; Madasamy Parani
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

5.  Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients.

Authors:  Lida Shojaei; Mostafa Mohammadi; Mohammad-Taghi Beigmohammadi; Mahsa Doomanlou; Alireza Abdollahi; Mohammad Mehdi Feizabadi; Hossein Khalili
Journal:  Iran J Microbiol       Date:  2016-10

6.  In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan.

Authors:  Dai Kurihara; Satoru Matsumoto; Naoko Kishi; Yoshikazu Ishii; Masahiko Mori
Journal:  Microbiol Spectr       Date:  2022-04-13

7.  Use of succinic & oxalic acid in reducing the dosage of colistin against New Delhi metallo-β-lactamase-1 bacteria.

Authors:  Ravichandiran Kumar; Brinda Chandar; Madasamy Parani
Journal:  Indian J Med Res       Date:  2018-01       Impact factor: 2.375
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.